Kunming Longjin Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Kunming Longjin Pharmaceutical Co Ltd working capital to net assets ratio. Kunming Longjin Pharmaceutical Co Ltd (002750) has a Working Capital to Net Assets ratio of 56.0% as of March 2025. Working capital of CN¥271.92 Million (current assets of CN¥311.11 Million minus current liabilities of CN¥39.19 Million) is measured against net assets of CN¥485.19 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 002750 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Kunming Longjin Pharmaceutical Co Ltd (2011–2024)
Working capital to net assets ratio of Kunming Longjin Pharmaceutical Co Ltd from 2011 to 2024. This chart shows how Kunming Longjin Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2011 to 2024. As of March 2025, the ratio stands at 56.0%, reflecting working capital of CN¥271.92 Million against net assets of CN¥485.19 Million CNY. See 002750 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Kunming Longjin Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2011–2024)
Kunming Longjin Pharmaceutical Co Ltd working capital to net assets ratio by year from 2011 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Kunming Longjin Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 002750 total assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 58.6% | CN¥289.54 Million | CN¥494.21 Million | CN¥338.18 Million | CN¥48.63 Million | ▼ -3.1 pp |
| 2023 | 61.7% | CN¥333.92 Million | CN¥541.13 Million | CN¥384.06 Million | CN¥50.14 Million | ▼ -1.7 pp |
| 2022 | 63.4% | CN¥383.38 Million | CN¥604.77 Million | CN¥471.04 Million | CN¥87.66 Million | ▲ +3.0 pp |
| 2021 | 60.4% | CN¥409.37 Million | CN¥678.29 Million | CN¥522.77 Million | CN¥113.40 Million | ▲ +0.8 pp |
| 2020 | 59.5% | CN¥419.33 Million | CN¥704.71 Million | CN¥519.61 Million | CN¥100.28 Million | ▲ +3.3 pp |
| 2019 | 56.2% | CN¥374.23 Million | CN¥665.89 Million | CN¥479.48 Million | CN¥105.25 Million | ▼ -0.7 pp |
| 2018 | 56.9% | CN¥373.13 Million | CN¥655.93 Million | CN¥472.57 Million | CN¥99.43 Million | ▲ +0.1 pp |
| 2017 | 56.8% | CN¥366.79 Million | CN¥645.54 Million | CN¥478.67 Million | CN¥111.89 Million | ▼ -1.1 pp |
| 2016 | 57.9% | CN¥388.23 Million | CN¥670.46 Million | CN¥449.76 Million | CN¥61.53 Million | ▲ +0.1 pp |
| 2015 | 57.8% | CN¥346.54 Million | CN¥599.41 Million | CN¥416.59 Million | CN¥70.05 Million | ▲ +53.8 pp |
| 2014 | 4.0% | CN¥11.42 Million | CN¥285.57 Million | CN¥136.50 Million | CN¥125.08 Million | ▲ +2.9 pp |
| 2013 | 1.1% | CN¥3.44 Million | CN¥302.00 Million | CN¥122.49 Million | CN¥119.05 Million | ▲ +4.0 pp |
| 2012 | -2.8% | CN¥-6.43 Million | CN¥226.94 Million | CN¥122.70 Million | CN¥129.13 Million | ▼ -12.3 pp |
| 2011 | 9.5% | CN¥17.73 Million | CN¥186.74 Million | CN¥107.85 Million | CN¥90.12 Million | — |